An interventional study of Paramedic Evaluation for acute COPD Exacerbation and Usual Care in COPD (Chronic Obstructive Pulmonary Disease), sponsored by University of Massachusetts, Worcester. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by University of Massachusetts, Worcester · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 139 open to participants now, 174 under way, 21 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.
Among the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 563rd largest by planned enrollment of the 1,039 interventional ones that give a count, is one of 45 that started in 2025, is one of 395 with no phase, reaches primary completion later than 143 of the 173 other live ones, and was the 1,216th registered.
5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →139 of the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:
University of California, Berkeley · Sites in United States
Ages 13+
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
GlaxoSmithKline · Sites in United States, United Kingdom
Ages 40–80
Johns Hopkins University · Sites in United States
Ages 18–75 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,280 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 117 · Phase 2 231 · Phase 3 239 · Phase 4 98
First in 1994; this study’s year is marked. 45 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 100 across the 1,039 interventional studies, 171 across the 237 observational. Of the 1,018 that completed or were terminated, 503 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
605 of 1,280 have an industry lead sponsor. The 10 most frequent:
University of Massachusetts, Worcester is the lead sponsor of 291 studies on the registry; 50 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
University of Massachusetts, Worcester has 6 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
62 of the studies in Pulmonary Disease, Chronic Obstructive with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05265299Phase 3Johns Hopkins UniversityTrial to Determine Effective Aspirin Dose in COPD | 2026-12 |
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT04968249University of MichiganMichigan Early Disease Progression Cohort | 2026-12 |
| NCT05879211Duke UniversityGoal Concordant Care Learning Laboratory | 2026-12 |
Add all 62 to your calendar (.ics) → With an account.
Among the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic Obstructive Pulmonary Disease (COPD) is a serious lung condition that affects millions of people in the United States. Each year, it leads to about 150,000 deaths, nearly 900,000 emergency room visits, and 700,000 hospital stays. When COPD symptoms suddenly get worse-called an exacerbation-it can seriously harm a person's quality of life and often requires emergency care. Treating these flare-ups early can help prevent hospital visits, but right now, there aren't many good ways to make sure people get care quickly.
Mobile Integrated Health (MIH) programs send specially trained paramedics, guided remotely by doctors, to care for patients in their homes. This approach could help people with COPD get faster, more effective care without needing to go to the hospital.
In this project, the investigators are testing a new program called PEACE (Paramedic Evaluation for Acute COPD Exacerbation). The PEACE program sends community paramedics to patients' homes-when needed and in partnership with their regular doctors-to manage worsening COPD symptoms early. The study team will adapt the PEACE program to meet the needs of adults living at home with moderate to severe COPD, gather feedback from patients and healthcare providers, and run a small pilot study to see if the program is practical and helpful.
Evidence-based strategies to ensure that patients with COPD have reliable, timely, equitable access to treatment are lacking. This deficit is particularly evident in communities impacted by determinants of health that adversely impact preventive health behavior and care access.
On-demand Mobile Integrated Health (MIH) teams, comprised of community paramedics supported by centralized physicians, have been developed to care for patients outside of conventional hospital settings. These teams empower physicians to provide enhanced remote care by collecting essential clinical information about patients in their living environment, performing diagnostic testing, and administering therapy in the home. MIH programs decrease emergency medical services utilization and improve patient satisfaction in select populations, but the impact of MIH programs on the outcomes of patients with COPD exacerbation has not been evaluated.
In this project, the study team will implement and refine an MIH intervention for patients living with COPD. The Paramedic Evaluation for Acute COPD Exacerbation (PEACE) intervention will dispatch community paramedics to execute a home-based evaluation and treatment strategy in collaboration with a supervising physician and the patient's ambulatory medical team during and after acute COPD exacerbation to promote wellness and recovery. This intervention is intended to improve clinical outcomes and reduce acute care costs by eliminating barriers to care, generating actionable clinical data that can facilitate appropriate diagnosis, accelerating treatment, and simplifying care coordination. Our central hypothesis, based on preliminary data and input from key informants, is that an intervention that facilitates community-based management of COPD exacerbation will be acceptable and highly adoptable by patients and clinicians.
The Practical Robust Implementation and Sustainability Model (PRISM) implementation framework will be used to describe factors impacting project implementation, with the embedded Expanded RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) model guiding outcomes measurements. Leveraging our prototypical intervention design, the study team will test and Refine the prototype PEACE intervention in real clinical practice with a cohort of patients who are at high risk of COPD exacerbation. The study team will use a mixed-methods approach to evaluate the usability and acceptability of each operational and clinical component of PEACE. Measures will include a systematic assessment of protocol adherence, survey instruments, and qualitative interviews to explore contextual factors impacting intervention performance. The study team will confirm our findings and adapt the protocols informed by a working group comprised of clinicians and community partners. Up to 25 patient participants will be enrolled in the intervention, plus up to 11 clinician participants will be enrolled to participate in usability/acceptability ratings and qualitative evaluations/focus groups.
The criteria were revised on the registry on Oct 2, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1) Diagnosis of 4) Receives care in the UMass Memorial Medical Center System 5) 40 years of age or older 6) Speaks English 7) Resides in the geographical catchment area allowed by the UMass Memorial Medical Center MIH Program's license
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this arm will receive PEACE Intervention
Procedure: Paramedic Evaluation for acute COPD Exacerbation
control arm participants will receive usual care
Procedure: Usual Care
The Paramedic Evaluation for Acute COPD Exacerbation (PEACE) program is a mobile integrated health initiative that aims to evaluate and treat COPD exacerbation in the home. The goal of the intervention is to expedite the recognition and treatment of COPD exacerbation as well as For this intervention, ambulatory teams can refer patients for PEACE visits when a patient has been identified as suffering from symptoms consistent with COPD exacerbation. Once a visit is requested via electronic health record order, a community paramedic presents to the patient's home within 2 hours, evaluates the patient using mobile diagnostic testing, and initiates pharmacological therapies protocolized by the pulmonary team. A standardized clinical approach and documentation strategy is used including a focused history and physical exam, venous blood gas, trending pulse-oximetry, and mobile x-ray. The community paramedic is supervised in real-time by an emergency physician to establish a care plan and di
Patients will receive care as usual. They will be asked to complete survey instruments as part of their participation in the study
Recruitment Rate
Ratio of patients enrolled to total patients approached
Time frame: At enrollment
Reason for Recruitment Refusal
Reason that approached patients did not enroll in the study
Time frame: At enrollment
Intervention Acceptability
Using the healthcare intervention acceptability qualitative framework, investigators will measure intervention acceptability from both patient and clinician perspectives. This validated framework assesses participants' affective attitudes, sense of intervention coherence, self-efficacy, the perceived ethicality of the intervention, intervention burden and anticipated cost, opportunity cost, and perceived effectiveness.
Time frame: from enrollment until completion of study activities at 1 year
Protocol Fidelity
Investigators will evaluate adherence to each component of the PEACE protocol by having two independent physician-reviewers audit the EHR and video recordings from every PEACE encounter to ensure that procedures were completed correctly and within the expected timeframe. Particular attention will be focused on visits with operational or clinical "failures," defined as any clinical or operational deviation from intervention protocol or any unexpected ED visit or hospitalization within 72 hours of a PEACE referral.
Time frame: From enrollment until study completion at 1 year
Sample Retention
Investigators will track the number of subjects who completed the entire study compared to the number of subjects initially enrolled. The investigators will also evaluate loss to follow-up rate, perceived reason for discontinuation and completeness of post-intervention data collection.
Time frame: From enrollment until completion of study activities at 1 year
PEACE Referrals
Investigators will track the total number of PEACE referrals requested during the study period
Time frame: 6 and 12 months after enrollment
PEACE Disposition
Distribution of participant clinical disposition after PEACE encounter (home versus emergency department)
Time frame: 6 and 12 months after enrollment
Unanticipated ED Visits
ED visits within 72 hours after PEACE visit where patient was treated in place
Time frame: From enrollment to completion of study activities at 1 year
Hospitalizations
Number and length of hospitalizations for COPD
Time frame: From enrollment until completion of study activities at 1 year
Exacerbation Relapse Rate
Number of occurrences when patients experience worsening COPD symptoms requiring a second pharmacological intervention before resolution of symptoms from a treated exacerbation
Time frame: From enrollment until completion of study activities at 1 year
COPD-related Medication changes
Number of adjustments made to study participants' COPD treatment regimen (initiation, discontinuation, dosage adjustment, or substitution of medications aimed at managing COPD)
Time frame: From enrollment to completion of study activities at 1 year
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Clinical and laboratory data: Includes medical history, demographic information, and patient characteristics at enrollment. Other data will be extracted from the electronic health record and patient-facing instruments at 3, 6, and 12 months. This includes healthcare utilization patterns, instances of COPD exacerbation relapse, COPD-related medication adjustments, and mortality. Additionally, patient-reported COPD-related quality-of-life instruments will be captured and tracked throughout the study. These values will be reported as tabular data and stored in a REDCap secure electronic data capture system. Interview data: Semi-structured interviews will be performed with patients, clinicians, and administrators. Deidentified, raw transcripts will be generated and coded using methods described in the research strategy. Codebooks will be developed and used for coding transcripts. Codebooks and coding summary files will be shared as detailed below.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Baseline data (data collected before any intervention), such as demographics, that require no additional analyses, will be submitted within 4 months after enrollment is completed. After the study is complete, the study team will submit all remaining scientific data to the data repository and will mark the RCT status as "complete" in clinicaltrials.gov. Under the current repository policies, data will be preserved and available for the wider research community in perpetuity.
Access criteria: Prior to the release of individual-level data, researchers will be required to complete data sharing and confidentiality agreements as established by the data repository. Researchers must commit to 1) not attempting to re-identify participants, 2) securing the data with appropriate technology and enforcing strict access rules, 3) destroying data after analyses are completed, 4) meeting any requirements as stipulated by the health system involved in the study, and 5) if research is conducted within a covered entity, HIPAA requirements must be met prior to use.
Started Oct 2025 (actual). Primary completion is estimated for Jul 2029, 45 months after the start.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 45 months is above that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
University of Massachusetts, Worcester →